It's tricky - the fact that the company are planning an investor roadshow through the EU and US seems to suggest they are keen to keep Avexa as Avexa - in other words, get a licensing deal while remaining an independent company. The board room appointments on the the other hand sound like a company looking to merge or be taken over. So, from the company's point of view, it seems like they are keeping their options open (and this is consistent with what I have heard from them). But the company may not be in the driver's seat here for too much longer.
The identity of the seller/buyer behind the nominee company dealing all the AVX shares of late is a mystery to the company and it's impossible to guess at who they are and what their motives might be. Seems the obvious thing would be a bit of price 'manipulation' in the lead up to a takeover, but I guess it could also be a prospective partner pushing down the SP to reduce AVX's bargaining power in any partnership deals.
AVX Price at posting:
12.7¢ Sentiment: Buy Disclosure: Held
